Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

Overview of attention for article published in Clinical & Experimental Metastasis, August 2008

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

patent: 8 patents

Citations

dimensions_citation: 169 Dimensions

Readers on

mendeley: 112 Mendeley
citeulike: 1 CiteULike

Summary Patents Dimensions citations

So far, Altmetric has seen 8 patents that reference this research output.

Methods and compositions for targeting cancer stem cells

Grant US-10398672-B2

United States of America

Selective targeting of cancer stem cells

Grant US-10106778-B2

United States of America

Methods for the treatment of cancer using gliadin peptides

Grant US-9669068-B2

United States of America

Methods of treating cancer sensitive to anti-EGFR therapy and modifying treatment using…

Grant US-9588122-B2

United States of America

Kits and methods for the treatment of cancer using gliadin peptides

Grant US-9254308-B2

United States of America

IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT

Application WO-2012049192-A1

World Intellectual Property Organisation (WIPO)

METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL-LIKE TUMOR CELLS OR…

Application WO-2010099138-A3

World Intellectual Property Organisation (WIPO)

METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL-LIKE TUMOR CELLS OR…

Application WO-2010099364-A3

World Intellectual Property Organisation (WIPO)